The efficacy and safety in radioactive iodine refractory thyroid cancer patients treated with sorafenib.

Yuanna Ling,Xiaoli Xiong,Jiaxin Luo, Quanliang Zou,Pan Chen,Liqin Pan, Man Long,Huijuan Feng,Wei Ouyang

Frontiers in endocrinology（2023）

引用 0|浏览3

暂无评分

摘要

Sorafenib has promising efficacy in RR-DTC, especially in patients with lung metastasis and lung-only metastasis. The AEs of sorafenib were generally mild, and the main AE was HFS.

查看译文

关键词

differentiated thyroid cancer,sorafenib,radioactive iodine refractory,real-world clinical study,efficacy and safety

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要